Citius Oncology, Inc.
NASDAQ:CTORDrug Manufacturers - General
+$0.03 today
- Market cap
- $51.83M
- Beta
- 3.42
- P/E (TTM)
- -1.6
- EPS (TTM)
- -$0.42
Volume 0.15M
Average 0.12M
CTOR Total Assets
Everything the company owns or controls; equal to total liabilities plus equity.
Citius Oncology, Inc.NASDAQ: CTOR
Total Assets · Q2 FY2026 · quarter ended Mar 2026
Total assets rises 10.1% from a year ago
Total assets stood at $100.7M at the end of Q2 FY2026, up 10.1% from a year earlier and down 8.4% from the prior quarter. Over 3 fiscal years it compounded at +33.2% a year.
Context
- Total assets increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total assets keeps rising in the next quarterly balance sheet after a +10.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Assets history
USD · from the balance sheet
- Latest · FY2025
- 100.94M USD
- Year-over-year change
- +19.6%
- 3-year CAGR
- +33.2%
| Period | Period end | Total Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 100.94M | +19.6% |
| FY2024 | 2024-09-30 | 84.37M | +76.7% |
| FY2023 | 2023-09-30 | 47.73M | +11.8% |
| FY2022 | 2022-09-30 | 42.69M | — |
Total Assets vs competitors
How CTOR compares with its peers on the latest reported figures
- CTOR's Mar 2026 total assets of $100.7M is the 5th highest of the 10 companies compared; the peer median is $86.76M.
- Its year-over-year change of +10.1% is the 6th highest of 10, against a peer median of +41.6%.
- Over three fiscal years its annual growth of +33.2% compares with a peer median of +8.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR |
|---|---|---|---|---|
| Mar 2026 | $506.75M | +363.6% | +15.7% | |
| Mar 2026 | $293.64M | +271.8% | +61.6% | |
| Mar 2026 | $284.92M | -28.5% | -23.3% | |
| Mar 2026 | $117.62M | -28.4% | -26.6% | |
CTORCitius Oncology, Inc. | Mar 2026 | $100.7M | +10.1% | +33.2% |
| Mar 2026 | $86.76M | +68.8% | +13.8% | |
| Mar 2026 | $67.22M | +41.6% | +25.4% | |
| Mar 2026 | $66.22M | -9.2% | +8.6% | |
| Mar 2026 | $59.02M | -24.0% | -18.0% | |
ACTUActuate Therapeutics Inc | Mar 2026 | $8.91M | +98.8% | -11.8% |
| Peer median (excluding CTOR) | $86.76M | +41.6% | +8.6% | |
Competitors are the stored peer set for CTOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Citius Oncology, Inc.
NASDAQ:CTOR
Intrinsic Alpha fair value
Locked
Current Price
$0.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.